Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine
- PMID: 18838298
- DOI: 10.1016/j.it.2008.07.010
Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine
Abstract
The gastrointestinal and vaginal mucosa are the major routes of natural HIV transmission, with the former being the primary reservoir for virus replication. The crucial need for a global HIV vaccine underscores the effort to develop vaccines capable of eliciting mucosal immune responses. Vaccines that induce high levels of effective mucosal immunity should impact viral replication rate and prevent dissemination of virus from the mucosa into the systemic circulation. In our opinion, the major effort for effective HIV vaccine should be concentrated on generating protective immunity at the site of viral entry (i.e. the gastrointestinal and vaginal mucosae). Here we examine the current information regarding the role of mucosal immunity in prevention of HIV transmission and discuss strategies for mucosal AIDS vaccine development.
Similar articles
-
Progress towards an AIDS mucosal vaccine: an overview.Tuberculosis (Edinb). 2007 Aug;87 Suppl 1:S35-44. doi: 10.1016/j.tube.2007.05.005. Epub 2007 Jul 24. Tuberculosis (Edinb). 2007. PMID: 17652028 Review.
-
Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.J Med Virol. 2003 Feb;69(2):163-72. doi: 10.1002/jmv.10279. J Med Virol. 2003. PMID: 12683403
-
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.J Infect Dis. 2004 Apr 1;189(7):1221-31. doi: 10.1086/382088. Epub 2004 Mar 15. J Infect Dis. 2004. PMID: 15031791 Clinical Trial.
-
Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.Curr Top Microbiol Immunol. 2012;354:157-79. doi: 10.1007/82_2010_119. Curr Top Microbiol Immunol. 2012. PMID: 21203884 Review.
-
Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.Trends Immunol. 2010 Mar;31(3):120-30. doi: 10.1016/j.it.2009.12.003. Epub 2010 Jan 19. Trends Immunol. 2010. PMID: 20089450 Review.
Cited by
-
Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.PLoS One. 2010 Sep 2;5(9):e12499. doi: 10.1371/journal.pone.0012499. PLoS One. 2010. PMID: 20824074 Free PMC article.
-
Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.Eur J Immunol. 2011 Dec;41(12):3513-28. doi: 10.1002/eji.201141453. Eur J Immunol. 2011. PMID: 21928282 Free PMC article.
-
Reactivation of latent HIV-1 by a wide variety of butyric acid-producing bacteria.Cell Mol Life Sci. 2012 Aug;69(15):2583-92. doi: 10.1007/s00018-012-0936-2. Epub 2012 Feb 10. Cell Mol Life Sci. 2012. PMID: 22322557 Free PMC article.
-
A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.Mucosal Immunol. 2016 Sep;9(5):1340-52. doi: 10.1038/mi.2015.133. Epub 2016 Jan 6. Mucosal Immunol. 2016. PMID: 26732678 Free PMC article.
-
T Helper 17 Promotes Induction of Antigen-Specific Gut-Mucosal Cytotoxic T Lymphocytes following Adenovirus Vector Vaccination.Front Immunol. 2017 Nov 6;8:1456. doi: 10.3389/fimmu.2017.01456. eCollection 2017. Front Immunol. 2017. PMID: 29163524 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials